Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Philip Arlen's Biography

Philip Arlen, President and CEO, Precision Biologics, Inc

Dr. Arlen is the company’s President, CEO and Chief Medical Officer. Prior to joining Precision Biologics, Inc., he served as President, CEO, and Chief Medical Officer at Neogenix Oncology, Inc. Dr. Arlen spent 11 years at the National Cancer Institute, USA, most recently as the Director of the Clinical Research Group for the Laboratory of Tumor Immunology and Oncology. At the NCI, Dr. Arlen focused on the development of a programmatic approach to vaccine clinical trials conducted at the NCI as well as at numerous other Cancer Centers throughout the U.S. During his tenure at the NCI, Dr. Arlen was the Principal Investigator and/or Associate Investigator on numerous clinical trials involving the use of cancer vaccines and other immuno-stimulatory molecules.

Dr. Arlen remains on the clinical staff at both the NCI Clinical Center as well as the Walter Reed National Military Medical Center. He has authored or co-authored over 100 peer reviewed manuscripts in internationally known scientific and medical journals. Dr. Arlen received an NIH Award of Merit for major contributions to the field of cancer immunotherapy in 2003. He is a board certified medical oncologist and received his BA from Emory University and his MD from Medical College of Georgia, School of Medicine.

Philip Arlen Image

Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes

Tuesday, 29 October 2019 at 10:00

Add to Calendar ▼2019-10-29 10:00:002019-10-29 11:00:00Europe/LondonDiscovery and Development of Monoclonal Antibodies Targeting Tumor Neo-EpitopesImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

An allogeneic cancer vaccine developed from human tumors surgically resected had demonstrated anti-tumor responses in a clinical trial. These responses correlated with the ability of patients to mount and sustain antibody responses against the vaccine. This vaccine was utilized as a platform to identify monoclonal antibodies with tumor sensitivity, specificity and anti-tumor killing.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The